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Abstract
Background: In Gabon, following the adoption of amodiaquine/artesunate combination (AQ/AS) as first-
line treatment of malaria and of sulphadoxine/pyrimethamine (SP) for preventive intermittent treatment
of pregnant women, a clinical trial of SP versus AQ was conducted in a sub-urban area. This is the first
study carried out in Gabon following the WHO guidelines.
Methods: A random comparison of the efficacy of AQ (10 mg/kg/day × 3 d) and a single dose of SP (25
mg/kg of sulphadoxine/1.25 mg/kg of pyrimethamine) was performed in children under five years of age,
with uncomplicated falciparum malaria, using the 28-day WHO therapeutic efficacy test. In addition,
molecular genotyping was performed to distinguish recrudescence from reinfection and to determine the
frequency of the dhps K540E mutation, as a molecular marker to predict SP-treatment failure.
Results: The day-28 PCR-adjusted treatment failures for SP and AQ were 11.6% (8/69; 95% IC: 5.5–22.1)
and 28.2% (20/71; 95% CI: 17.7–38.7), respectively This indicated that SP was significantly superior to AQ
(P = 0.019) in the treatment of uncomplicated childhood malaria and for preventing recurrent infections.
Both treatments were safe and well-tolerated, with no serious adverse reactions recorded. The dhps
K540E mutation was not found among the 76 parasite isolates tested.
Conclusion: The level of AQ-resistance observed in the present study may compromise efficacy and
duration of use of the AQ/AS combination, the new first-line malaria treatment. Gabonese policy-makers
need to plan country-wide and close surveillance of AQ/AS efficacy to determine whether, and for how
long, these new recommendations for the treatment of uncomplicated malaria remain valid.
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Background
Chloroquine (CQ) resistance is widespread in Gabon and
this forced the health authorities to revise the national
malaria treatment policy [1,2]. In July 2003, following a
national consensus meeting, the Gabonese Ministry of
Health responded to WHO recommendations by adopt-
ing the amodiaquine/artesunate (AQ/AS) combination as
first-line treatment, the artemether/lumefantrine (A/L)
combination as second-line treatment, sulphadoxine/
pyrimethamine (SP) for preventing malaria in pregnant
women; quinine remains the treatment of choice for
severe malaria. Despite the considerable efforts of the Glo-
bal Fund to help fighting malaria, the implementation of
the WHO-recommended artemisinin-based combination
treatments (ACTs) for controlling malaria encounters tre-
mendous challenges in low-income countries, particularly
in sub-Saharan Africa, because of the high cost of the
drugs. Moreover, sound data supporting this new antima-
larial-treatment policy is lacking in Gabon, and most in
vivo studies to evaluate efficacy have been conducted with
variable methodologies. Most previous studies were car-
ried out in three provinces, namely Estuaire, Moyen-
Ogooué and Haut-Ogooué, but none in Gabon's other six
provinces. Consequently, studies carried out at the
national level according to a standardized WHO protocol
[3] were needed to determine the efficacy level of all anti-
malarial drugs to be used in the new national malaria
treatment policy.
According to the data reported in the literature, Plasmo-
dium falciparum CQ resistance was first reported in vitro in
Gabon in 1983 [4] and confirmed by subsequent studies
conducted throughout the country between 1984 and
1985 [5]. In 1987, CQ resistance was reported to have
spread very fast, with an average reported rate of 42% [5].
Although this level of CQ resistance has remained stable
since [6,7], there was a need to change this treatment pol-
icy. The situation was similar in neighbouring countries
[8-10]. It has been reported that an increase of infant mor-
tality was attributable to the escalating P. falciparum resist-
ance to CQ [11]. In Gabon, CQ has been used for many
years as first-line drug for treating uncomplicated malaria
and for preventing malaria. AQ and SP are the only cheap
and widely available antimalarials and they were used
together as second-line drugs before the change in drug
policy. Regarding AQ efficacy, Gabon is an unusal case
amongst Central African countries, because of regional
differences. All studies carried out in Libreville (Estuaire
province) demonstrated a good efficacy of AQ, with resist-
ance rates below 15% [1,2,12], while those conducted in
Lambarané (Haut-Ogooué province) and in Bakumba
(Moyen-Ogooué province) reported unacceptable resist-
ance rates, higher than 25% [13,14]. A better understand-
ing of the factors responsible for regional differences in
AQ efficacy would be helpful to guide anew malaria treat-
ment policy. The only previous studies assessing efficacy
of SP were conducted in Franceville (Haut-Ogooué prov-
ince) reporting a good efficacy of SP with clinical resist-
ance rates below 10% [15]. A clinical trial testing the
efficacy of AS monotherapy conducted in Lambarané
showed an excellent clinical efficacy with a PCR-corrected
28-day cure rate of 90% [16].
If the strategy of combining two or more antimalarial
drugs is widely recommended as a means for improving
treatment efficacy and delaying the development of resist-
ance, a knowledge of the resistance level against individ-
ual components of the combination is essential. Policy-
m a k e r s  i n  G a b o n  u r g e n t l y  n e e d  t o  k n o w  w h e t h e r  t h e
newly-adopted malaria treatment strategy is a viable
option in terms of therapeutic efficacy. They also need to
learn how best to use information from clinical trials for
optimizing the policy or considering when to make a fur-
ther change in treatment policy.
The objectives of this study were to determine the efficacy
level of AQ and SP using the standard WHO 28-day ther-
apeutic efficacy test, with PCR-genotyping to distinguish
recrudescences from reinfections due to therapeutic fail-
ures. Additionally, the prevalence of the dhps K540E muta-
tion, previously defined as a predicting tool of SP-
resistance [17], was also assessed. This is the first such




Gabon is a Central African country bordering Equatorial
Guinea and Cameroon to the north, and the Republic of
Congo to the east. It has a 800 km coastline, providing
access to the Atlantic Ocean to the west. It is situated on
the equator and, hence, has a hot and humid climate, with
precipitation nine months out of twelve. A dense forest
covers 85% of its territory. Officially, Gabon's population
is approximately 1.5 million, with 80% of the population
living in towns. There are eight main ethnic groups, which
are spread out across the country, but more than forty dif-
ferent ethnic groups altogether. On an administrative
level, Gabon is subdivided into nine provinces, namely:
Estuaire; Haut-Ogooué; Moyen Ogooué; Ngounié;
Nyanga; Ogooué-Ivindo; Ogooué-Lolo; Ogooué-Mari-
time; and Woleu-Ntem. The rainy season is from October
to May, and the dry season is from June to September.
Malaria transmission is perennial with seasonal fluctua-
tions.
Study site
This study was carried out between March-July 2005 in
Oyem, a town of the Woleu-Ntem province of 35,000
inhabitants, near the northern borders with CameroonMalaria Journal 2008, 7:31 http://www.malariajournal.com/content/7/1/31
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and Equatorial Guinea, and 411 km away from Libreville
(the political and administrative capital) to the south-
west. Malaria is hyperendemic and transmission is peren-
nial. In this forest region, where Anopheles gambiae s.s is
considered to be the most important vector of malaria, the
Plasmodium  index in children under 15 years of age is
ranging from 65% to 73%, indicating an intense malaria
transmission [18].
Patient recruitment
The study was conducted in fchildren with fever, below
five years of age, attending the Out-patient Department of
Oyem Hospital. Using the 28-day WHO therapeutic test
for intense transmission areas of malaria [3], patients
were enrolled in the study if they satisfied the following
inclusion criteria: age between 6–59 months, mono-infec-
tion with P. falciparum, parasitaemia ≥ 2,000 asexual par-
asites per μL of blood, free from severe malnutrition,
absence of general danger signs or severe malaria, an axil-
lary temperature of 37.5°C or above, absence of febrile
conditions caused by diseases other than malaria, ability
to come for the stipulated follow-up visits and easy access
to the health facility, informed consent of parent/guard-
ian, absence of history of hypersensitivity reactions to sul-
phonamides, and at least 5 g haemoglobin (Hb)/dL.
Neither a history of previous antimalarial drug use, nor
the presence of antimalarial drugs in the urine was an
exclusion criterion in the WHO standard protocol [3,19].
Before enrolment in the study, a medical history of each
patient was obtained from their accompanying parent or
guardian and the child was clinically examined by a phy-
sician. Body weight and axillary or ear temperature were
recorded; thick and thin smears were Giemsa-stained (5%
Giemsa R for 20 min.) for parasite identification and
quantification. Parasitaemia (parasites/μL) was measured
by counting the number of asexual parasites against 200
leucocytes in the Giemsa-stained thick blood smears,
based on a mean count of 8,000 leucocytes per μL of
blood. A slide was declared negative only after micro-
scopic fields corresponding to at least 500 leucocytes had
been checked. Two experienced technicians performed
the microscopy independently, each time comparing their
results. The principal investigator closely supervised the
study team to ensure consistency and accuracy of the data.
Some slides randomly chosen were re-read in the labora-
tory in Paris.
Sample size estimations for the therapeutic test were per-
formed by assuming that the treatment failures rate would
be significantly less than 15% for SP and AQ, referring to
previous clinical trials outcomes. Thus, according to WHO
recommendations, a minimum of 50 patients was
required for each therapeutic group [3].
Patient treatment and follow-up
After obtaining informed consent from parents or guardi-
ans on day 0, the enrolled children were randomly allot-
ted to one of two treatment groups, to receive either AQ
base (Camoquin® tablets, Pfizer, Dakar, Senegal) 30 mg/
kg body weight over three days (i.e. 10 mg/kg daily), or SP
(Maloxine® tablets, Exphar, Belgium) as a single dose of 25
mg/kg of sulphadoxine/1.25 mg/kg of pyrimethamine.
An antipyretic (paracetamol, 15 mg/kg, every 8 h for 24 h)
was systematically given on day 0 and if needed on day 1
and 2. All tablets were administered orally by a nurse in
the presence of the physician. For 30 min following drug
administration, patients were observed for vomiting and
other side-effects. The same dose was re-administered if
vomiting occurred. On days 1 and 2, symptoms, other
medications, temperature, and physical examination were
recorded, but microscopy was not performed unless one
or more of danger signs were present. The same clinical
observation was repeated and parasitological examina-
tion was conducted on days 3, 7, 14, 21 and 28. On day 0,
when the patient presented a fever without parasitaemia
in the absence of another pathology the child was seen on
the next day for intensive follow-up and microscopic diag-
nosis of malaria. All treatment failures were treated with
quinine tablets (8 mg/kg base three times daily for seven
days).
Classification of treatment outcomes
The responses to drug treatment were classified according
to the WHO protocol [3], as an adequate clinical and par-
asitological response (ACPR), early treatment failure
(ETF), and late treatment failure (LTF), including late clin-
ical failure (LCF) and late parasitological failure (LPF).
Molecular genotyping of parasite isolates
Finger-prick blood samples blotted on Isocode®  filter
papers (Schleicher and Schuell, Ecquevilly, France) were
dried and stored at room temperature in small separated
and sealed plastic bags, prior to genotyping analysis at the
National Malaria Reference Centre, Bichat-Claude Ber-
nard Hospital, Paris, France. DNA was extracted with
chelex-100 resin as previously reported [20]. Merozoite
surface protein-2 (msp-2), which has been shown to be
sufficiently discriminating in African parasite populations
[21], was amplified by PCR for paired pre-treatment and
failure samples to distinguish recrudescences from rein-
fections, as previously described [22]. Genotyping results
PCR-adjusted were classified into three categories: 1) true
recrudescences, 2) reinfections, and 3) mixed results
(recrudescence and reinfection). Treatment outcomes
with PCR correction were based on the number of recru-
descences and reinfections, as indicated elsewhere [23].
The cases of mixed results were considered as recrudes-
cences, and unconclusive results (PCR-DNA amplificationMalaria Journal 2008, 7:31 http://www.malariajournal.com/content/7/1/31
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failure) were excluded from the analysis. In addition,
PCR-genotyping followed by sequencing method, as pre-
viously reported [17], was performed for assessing the
prevalence of dhps K540E mutation.
Ethical considerations
The local health and institutional authorities approved
the research protocol (Gabonese Ministry of Public
Health). Verbal and written informed consent for partici-
pation were obtained from parents or guardians, after
thorough information on the study was provided in the
local language.
Statistical analysis
Data were analysed using version 2000 of the Epi-info
software (Centers for Disease Control and Prevention,
Atlanta, GA) and Graphpad Instat software (Graph Pad
software, 10855 Sorrento Valley Road #203, San Diego
CA92121 USA). Proportions were compared by perform-
ing Fisher's Exact test. The therapeutic response at day-28
of follow-up with its corresponding 95% confidence
intervals was calculated using an intention-to-treat analy-
sis, which included all patients who fulfilled enrolment
criteria. Standard deviation (SD) was generally indicated
for means and P-values of < 0,05 were calculated to dem-
onstrate differences statistically.
Results
Of the 632 febrile children with suspected malaria who
were screened, three hundred-two (47.8%; 302/632) had
confirmed malaria, of whom 154 met the inclusion crite-
ria. Three hundred forty-four (54.4%; 344/632) were
male; their mean age was 32.2 months.
Of the 154 enrolled children, 78 were randomly assigned
to AQ and 76 to SP. No difference was observed between
the two therapeutic groups in terms of gender, mean age,
mean body weight, presence of documented fever (axil-
lary temperature ≥37.5°C) and parasitaemia. Overall,
fourteen patients were excluded or lost to follow up
(seven in AQ group and seven in SP group) during the fol-
low-up period because of failure to follow the protocol
(antimalarial treatment administered by themselves or a
third party) or failure to come for follow-up on the sched-
uled days (generally because of travel for several days out-
side the city). Details of the patient follow-up are reported
in Figure 1 (trial profile). No severe adverse drug reactions
were observed during the follow-up of the patients in any
therapeutic group. The day-28 PCR-adjusted failure rates
were significantly higher in the AQ (28.2% 20/71; 95%
CI: 17.7–38.7) group than in the SP group (11.6% 8/69;
95% CI: 5.5–22.1), (P = 0.0195). Of the 32 late treatment
failures recorded in AQ group, detailed PCR-genotyping
results were as following: 13 recrudescences, six reinfec-
tions, seven mixed results (recrudescence + reinfection)
and six unconclusive results (PCR-amplification failure).
Regarding SP group, detailed PCR-genotyping results
among 14 late treatment failures were as following: eight
true recrudescences and six reinfections. SP was superior
to AQ for preventing recurrent infections (Table 1). The
dhps K540E mutation was not found among the 76 ana-
lysed blood samples from patients allocated to the SP
group.
Discussion
The results of this study show, both clinically and parasi-
tologically, that SP is significantly superior to AQ in terms
of efficacy, with day-28 PCR-corrected failure rates of
11.6% and 28.2% respectively. SP also was more effective
than AQ for preventing recurrent infections. Both regi-
mens were safe and well-tolerated, with no serious
adverse reaction recorded during the course of the study.
Although protocols of previous studies were not in con-
formity with the standard WHO protocol, our data con-
cerning SP efficacy are consistent with those reported in
other parts of the country, such as in Bakoumba (Haut-
Ogooué province) indicating a treatment failure rate of
14% at day 28 without PCR-adjustment in children under
10 years [14]. A good efficacy of SP was also observed in
neighbouring Congo, Cameroon and Equatorial Guinea
[9,10,24]. The absence of the dhps  K540E mutation
observed in the present study was already described in
Gabon [25] and in neighbouring countries [17,25,26].
There is now a clear evidence that the principal role attrib-
uted to the dhps K540E mutation as a molecular marker
predicting clinical SP-treatment failures is not true either
in the existing literature or in the present study where
11.6% of SP resistance was found without a single
instance of dhps K540E mutation. The AQ-resistance level
reported in the study is too high, according to WHO
guidelines (AQ-treatment failures >25%). The present
results regarding AQ efficacy are consistent with other
studies from Lambarané (Moyen-Ogooué province) and
Bakumba (Haut-Ogooué province), reporting worse AQ
efficacy with PCR-uncorrected resistance rates ranging
from 34.7% to 47% on day 28 [13,14]. In contrast, the
results from Libreville (Estuaire Province) have reported
low AQ-failure rates ranging from 0% to 13% on day 14
[1,2,12]. Though these data are lacking PCR-adjustment,
it seems that AQ efficacy is creating geographic differences
in Gabon. Further AQ efficacy studies carefully carried out
according to standard WHO protocol in other parts of the
country, including settings reporting high AQ-failure
rates, are urgently needed. Geographic differences of AQ
efficacy cannot be directly explained by differences in
malaria transmission levels between different regions of
the country, because it was reported that transmission
intensity does not directly affect the evolution of drug-
resistance [27]. However, the relative importance of
immunity in determining the response to therapy hasMalaria Journal 2008, 7:31 http://www.malariajournal.com/content/7/1/31
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Trial Profile Figure 1
Trial Profile. AQ = amodiaquine; SP = sulphadoxine/pyrimethamine.
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been demonstrated in other studies, which had shown
that age, a surrogate marker of acquired immunity, is asso-
ciated with the ability to clear parasites with resistant gen-
otypes [28]. It has been reported that cytochrome P450
CYP2C8 is involved in the metabolism of AQ, and addi-
tionally some information is currently available concern-
ing its variation among ethnic groups as in Zanzibar and
in Ghana [29,30]; this also needs to be investigated in
Gabon in order to understand these inter-provincial dif-
ferences of AQ efficacy.
In conclusion, geographical differences of AQ efficacy dis-
cussed in this study are a major concern in Gabon now
that the AQ/AS combination has been selected as the new
malaria first-line treatment policy. Thus, further investiga-
tions carefully conducted in the respect of good clinical
practices are necessary to ascertain AQ-resistance at the
national level.
In a country where ACTs are implemented, classical anti-
malarial drugs, including AQ and SP, must be monitored
by recruiting persons with asymptomatic P. falciparum
infection. The results of this longitudinal prospective
study will provide an essential baseline of the parasitolog-
ical efficacy of those monotherapies and also to be able to
understand, at a later stage, the natural history of the evo-
lution of resistance to ACTs.
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